{"filings":[{"id":1058638,"accession_number":"0001104659-26-074102","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-06-15T21:00:27+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora names Samantha Hammock as CHRO replacing retiring Silvana Battaglia","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Silvana Battaglia retires as EVP & CHRO effective July 12, 2026 after 7 years.","Samantha Hammock joins as EVP & CHRO on July 13, 2026 from Verizon Communications.","Battaglia will serve as special advisor through end of 2026 to ensure transition.","Hammock will report to CEO Bob Mauch as part of enterprise leadership team.","Battaglia's departure was not due to any disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748879,"accession_number":"0001104659-26-068357","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-05-29T21:10:04+00:00","items":["5.02","1.01","7.01","9.01"],"status":"ready","headline":"Cencora appoints Eva Boratto as EVP and CFO, effective June 29, 2026; reaffirms FY2026 EPS guidance $17.70-$17.90","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appoints Eva Boratto as EVP and CFO effective June 29, 2026; succeeds James Cleary retiring.","Boratto receives $1M base salary, 100% bonus target, $2M cash sign-on bonus, $6M RSU with 3-year vesting.","Reaffirms FY2026 adjusted diluted EPS guidance $17.70-$17.90; previously $17.65-$17.90 after May share repurchases.","Reaffirms long-term guidance: adjusted operating income growth 7-10%, adjusted EPS growth 10-14%.","Boratto most recently CFO at Bath & Body Works; prior CFO at CVS Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91536,"accession_number":"0001140859-26-000018","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q2 revenue $78.4B (+3.8%); adj. EPS $4.75 (+7.5%); FY2026 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $8.40 vs $3.68; adjusted diluted EPS $4.75 vs $4.42 (+7.5%).","Revenue $78.4 billion, up 3.8% year-over-year.","FY2026 adjusted diluted EPS guidance raised to $17.65-$17.90 from $17.45-$17.75.","Expects to repurchase ~$1B of shares by end of calendar 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":11.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":164287932000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101685,"accession_number":"0001104659-26-033022","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cencora to buy EyeSouth retina business for $1.1B; expects slight EPS accretion","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquires EyeSouth Partners' retina business for $1.1B; physicians to join Retina Consultants of America.","Deal expected to be slightly accretive to adjusted diluted EPS in first 12 months post-close.","Cencora reaffirms fiscal 2026 financial guidance; transaction not yet reflected in guidance.","Transaction subject to regulatory approvals and customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101684,"accession_number":"0001104659-26-029039","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora CFO James F. Cleary to retire June 30, 2026; FY2026 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James F. Cleary, EVP and CFO, will retire effective June 30, 2026; advisory role through end of 2026.","Cencora has engaged an executive search firm to identify internal/external successors.","Company reaffirms FY2026 adjusted diluted EPS guidance range of $17.45 to $17.75.","Cleary, 62, joined in 2015 and has served as CFO since November 2018; no disagreement prompted departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101683,"accession_number":"0001140859-26-000014","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cencora shareholders elect all 11 directors, approve say-on-pay, ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; for votes ranged from ~163.3M to ~168.5M, with broker non-votes of 9.7M.","Advisory vote on fiscal 2025 named executive officer compensation approved: 156.9M for, 11.4M against, 0.4M abstain.","Ratification of Ernst & Young as independent auditor for FY 2026 approved: 165.7M for, 12.6M against, 0.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101682,"accession_number":"0001104659-26-016785","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cencora merges MWI Animal Health with Covetrus in $3.5B deal; receives cash, preferred and common equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["MWI valued at $3.5B enterprise value; Cencora gets $1.25B cash, $800M preferred units, $1.45B common units.","Cencora will hold a non-controlling 34.3% common equity stake in the combined company post-closing.","Transaction subject to regulatory approvals and customary closing conditions; no set closing date.","Cencora reaffirms fiscal 2026 guidance; deal not currently expected to close in FY2026 ending Sep 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101681,"accession_number":"0001104659-26-015272","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Cencora closes $3.0B senior notes offering, proceeds to repay OneOncology acquisition debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M each of 3.950% notes due 2029, 4.250% notes due 2030, 4.600% notes due 2033, 5.650% notes due 2056; $1.0B of 4.900% notes due 2036.","Net proceeds will repay amounts outstanding under a 364-Day Term Credit Agreement used to fund a portion of the OneOncology acquisition; remainder for general corporate purposes.","Offering closed Feb 13, 2026; joint book-runners: Citigroup, J.P. Morgan, BofA Securities, Wells Fargo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101680,"accession_number":"0001104659-26-013465","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cencora prices $3.0B senior notes offering across five tranches to repay OneOncology acquisition debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$3.0B aggregate of senior notes in five tranches: 2029 (3.950%), 2030 (4.250%), 2033 (4.600%), 2036 (4.900%), 2056 (5.650%).","Net proceeds (~$2.98B) to repay 364-Day Term Loan (used for OneOncology) and for general corporate purposes.","Offering expected to close February 13, 2026; joint book-runners: Citigroup, J.P. Morgan, BofA, Wells Fargo.","Offered under shelf registration filed Nov 26, 2024; underwriting agreement entered Feb 10, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101679,"accession_number":"0001140859-26-000012","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cencora reorganizes segments; explores strategic alternatives for MWI Animal Health, Profarma, U.S. Consulting Services","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["New segments: U.S. Healthcare Solutions, International Healthcare Solutions, and Other.","Other includes MWI Animal Health, Profarma, U.S. Consulting Services, and legacy Pharmalex components under strategic review.","Segment reporting change effective Q1 FY2026; historical segment data in 2025 10-K revised but consolidated financials unchanged.","No updates on events after November 25, 2025; first quarter FY2026 10-Q filed February 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101678,"accession_number":"0001140859-26-000004","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q1 EPS $2.87 GAAP, $4.08 adjusted; acquires OneOncology for $4.6B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $85.9B, +5.5% YoY; GAAP diluted EPS $2.87 vs $2.50 prior year; adjusted diluted EPS $4.08 vs $3.73, +9.4%.","Completed acquisition of OneOncology on Feb 2 for ~$4.6B in cash funded by new debt; operations consolidated in U.S. Healthcare Solutions.","Adjusted operating income guidance raised to growth of 11.5%-13.5% from prior 8%-10%; adjusted EPS guidance reaffirmed at $17.45-$17.75."],"consensus_eps_estimate":null,"consensus_eps_actual":2.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":85932016000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101677,"accession_number":"0001104659-26-005604","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora elects Ellen Cooper, CEO of Lincoln Financial, to its board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ellen Cooper appointed independent director effective Jan. 20, 2026; board expands from 10 to 11 members.","Cooper is Chairman, President, and CEO of Lincoln Financial; previously at Goldman Sachs, AEGON, and EY.","She will receive standard non-employee director compensation, pro-rated through 2026 annual meeting.","No committee assignment yet; no related-party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101676,"accession_number":"0001104659-26-004524","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cencora secures $5.5B in financing for OneOncology acquisition; $4.5B bridge replaced","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility increased by $1.0B to $5.5B via amendment on Jan 12, 2026.","Entered $1.5B term loan facility ($500M Tranche One, $1.0B Tranche Two) to fund acquisition.","Entered $3.0B 364-day term loan facility to pay consideration and fees for acquisition.","Existing $4.5B bridge financing automatically reduced to zero upon new facilities.","Interest margins range from 75-125 bps over SOFR; leverage covenant max 4.00x with potential increase to 4.50x."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118014,"accession_number":"0001104659-25-120852","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cencora acquires OneOncology majority stake for $3.6B, retires $1.3B debt; total cash ~$5.0B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value $7.4B; Cencora paying $3.6B for majority equity and retiring $1.3B OneOncology debt.","Acquisition expected to close by end of fiscal Q2 2026, subject to regulatory approvals.","Cencora paused share repurchases; FY2026 adjusted EPS guidance reiterated but likely lower half of $17.45-$17.75.","Long-term guidance raised: adjusted operating income growth 7-10%, adjusted EPS growth 10-14%.","Financing via new debt; $4.5B bridge financing committed; committed to investment grade ratings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118013,"accession_number":"0001140859-25-000128","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q4 adj EPS $3.84 (+15%); revenue $83.7B; raises dividend 9%; new segment structure","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $(1.75) (prior yr $0.02); adjusted EPS $3.84 (+15% YoY); revenue $83.7B (+5.9%).","FY2025 revenue $321.3B (+9.3%); GAAP EPS $7.96; adjusted EPS $16.00 (+16.3%).","Quarterly dividend increased 9%; long-term guidance raised.","New reporting structure Q1 FY26: U.S. Healthcare Solutions, Intl Healthcare Solutions, Other (under strategic review: MWI, Profarma, U.S. Consulting).","U.S. Healthcare Solutions FY2025 op income $3.28B (1.15% margin); Intl Healthcare op income $588M (2.07%)."],"consensus_eps_estimate":null,"consensus_eps_actual":7.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":321332819000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134471,"accession_number":"0001104659-25-088665","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Cencora amends term loan maturity to Oct 2027; money market facility limit raised to $750M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Term Loan maturity shortened from Jan 2028 to Oct 1, 2027; interest margin unchanged at 62.5-125 bps over Term SOFR.","Money Market Facility limit raised to $500M (Apr-Nov) and $750M (Dec-Mar), up from prior amounts.","Two lenders (Citibank, Societe Generale) exited the term loan, with loans reassigned to other lenders.","Money market facility remains uncommitted; Société Générale continues as sole lender.","No new borrowing drawn; amendments modify existing credit terms and capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134470,"accession_number":"0001104659-25-087080","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cencora reaches $111.3M settlement of derivative suit over opioid oversight","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Insurance carriers to pay Cencora $111.3M (less attorney fees) to settle derivative claims over controlled substance diversion controls.","Settlement subject to Delaware Chancery Court approval; defendants deny any wrongdoing or liability.","Derivative complaint alleged breach of fiduciary duty by directors and officers for failing to monitor opioid compliance.","Special Litigation Committee investigated and mediated the resolution; $111.25M mediator proposal accepted June 2025.","Settlement separate from Cencora's prior $6.4B nationwide opioid distributor settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134469,"accession_number":"0001104659-25-084068","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora appoints D. Mark Durcan as Chairman effective Oct 1, 2025; Steven H. Collis retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["D. Mark Durcan named Chairman of the Board, effective October 1, 2025, succeeding Steven H. Collis.","Collis retires as Executive Chairman and director at end of fiscal year September 30, 2025; no disagreement cited.","Board size reduces from 11 to 10 directors upon Collis's retirement.","Durcan has been a director since 2015 and Lead Independent Director since March 2023; former CEO of Micron Technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134468,"accession_number":"0001140859-25-000119","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q3 FY2025 revenue $80.7B (+8.7% YoY); adj. EPS $4.00, guidance raised to $15.85-$16.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $80.7B (+8.7% YoY); GAAP diluted EPS $3.52 vs $2.42; adj. EPS $4.00, up 19.8%.","Raised FY2025 adj. diluted EPS guidance to $15.85–$16.00 from $15.70–$15.95.","GAAP operating income $0.9B; adjusted operating income $1.1B; net income $687M GAAP / $781M adjusted.","Effective tax rate 23.0% GAAP, 20.7% adjusted; diluted shares 195.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":9.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":237604265000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134467,"accession_number":"0001104659-25-065769","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cencora increases receivables facility to $1.5B and doubles accordion to $500M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Receivables securitization facility raised to $1.5B from $1.45B; accordion feature increased to $500M from $250M.","New uncommitted purchaser Gotham Funding joined the facility; accordion now available in any quarter.","Facility provides additional liquidity backed by AR from ABDC and ASD; Cencora remains performance guarantor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151316,"accession_number":"0001104659-25-057300","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Cencora upsizes revolver to $4.5B, extends maturity to 2030; terminates $1.0B 364-day facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended revolving credit facility increased to $4.5 billion aggregate commitments; maturity extended to June 4, 2030.","Interest margins range from 69.5 to 110 bps over Term SOFR (or equivalent) based on credit ratings; facility fee 5.5-15 bps.","Terminated the $1.0 billion 364-day credit agreement originally set to expire January 1, 2026.","Term loan agreement amended to align covenants and pricing with the revolver; leverage ratio covenant remains at 4.0x (4.5x post-material acquisition).","Leverage ratio covenant set at 4.00 to 1.00; may rise to 4.50 to 1.00 after a Material Acquisition over $500 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151315,"accession_number":"0001104659-25-053623","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora adds Lori Ryerkerk to board; director Barra resigns amid WBA stake drop","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lori J. Ryerkerk, former Celanese CEO, elected independent director effective June 1, 2025.","Ornella Barra resigned from Cencora board effective May 27, 2025, as Walgreens ownership expected to fall below 5%.","Barra served since 2015; resignation not due to any disagreement with company.","WBA will lose director designation rights when ownership falls below 5%; no replacement director currently planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151314,"accession_number":"0001104659-25-051974","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Cencora issues €1B in senior notes across 2028 and 2032 maturities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €500M of 2.875% Senior Notes due May 22, 2028.","Issued €500M of 3.625% Senior Notes due May 22, 2032.","Notes are unsecured and rank equally with existing unsecured debt.","Interest payable annually starting May 22, 2026; notes redeemable at make-whole or par.","Issued under supplemental indentures with U.S. Bank Trust as trustee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151313,"accession_number":"0001104659-25-050462","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cencora prices €1B dual-tranche senior notes (2.875% due 2028, 3.625% due 2032)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€500M 2.875% senior notes due 2028 and €500M 3.625% senior notes due 2032 issued.","Net proceeds estimated at ~€994M after discounts and expenses; intended for general corporate purposes.","Notes are senior unsecured; closing expected on May 22, 2025.","Underwriters include BNP Paribas, Citigroup, J.P. Morgan, Société Générale.","Offering registered under shelf registration statement (Nos. 333-283481) filed Nov 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151312,"accession_number":"0001140859-25-000081","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q2 FY2025 revenue $75.5B (+10.3% YoY); adj. EPS $4.42 (+16.3%); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $75.5B, +10.3% YoY; GAAP diluted EPS $3.68 vs $2.09 prior year.","Adjusted diluted EPS $4.42, up 16.3% from $3.80; adjusted net income $863M.","FY2025 adjusted diluted EPS guidance raised to $15.70-$15.95 from $15.30-$15.60.","CEO Robert Mauch highlights strength of value proposition and pharmaceutical distribution."],"consensus_eps_estimate":3.8777,"consensus_eps_actual":6.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":156940733000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170199,"accession_number":"0001104659-25-022205","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cencora shareholders elect 11 directors, approve executive compensation, ratify EY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected; Lon Greenberg received highest opposition with 15.7M against votes.","Advisory vote on named executive officer compensation passed: 156.9M for, 12.3M against.","Ratification of Ernst & Young as FY2025 auditor approved: 166.3M for, 12.4M against.","Broker non-votes on director elections and advisory vote totaled 9.5M shares.","Annual meeting held March 6, 2025; all three proposals described in January 23 proxy statement approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170198,"accession_number":"0001104659-25-021947","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Cencora raises FY2025 adjusted EPS guidance range by $0.05 to $15.30-$15.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Guidance increase driven by continued momentum in U.S. Healthcare Solutions segment during Q2 2025.","No change to expectations for recently completed Retina Consultants of America acquisition.","Adjusted diluted EPS excludes acquisition intangibles, LIFO, litigation, and other items.","Company presented updated guidance at Leerink Partners Global Healthcare Conference on March 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170197,"accession_number":"0001104659-25-010980","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cencora repurchases $50M of common stock from Walgreens Boots Alliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 204,491 shares at price equal to Walgreens' Rule 144 sale, aggregate $50M.","Repurchase concurrent with Walgreens' sale of 1,081,885 shares under Rule 144 and early VPF settlements.","Walgreens retains ~6.5% stake (12.57M shares) after these transactions, shares still pledged.","Repurchased shares held in treasury under existing share repurchase program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170196,"accession_number":"0001140859-25-000032","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q1 revenue $81.5B +12.8% YoY; adjusted EPS $3.73, raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $81.5B (+12.8% YoY); GAAP diluted EPS $2.50 (down from $2.98); adjusted diluted EPS $3.73 (+13.7%).","Adjusted diluted EPS guidance raised to $15.25-$15.55 from $15.15-$15.45 for fiscal 2025.","Closed acquisition of Retina Consultants of America on Jan 2, 2025 to strengthen specialty leadership.","GAAP operating income $706M; adjusted operating income $949M; net income attributable $489M GAAP, $728M adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":2.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":81487060000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170195,"accession_number":"0001140859-25-000011","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Cencora directors to retire at March 6 annual meeting; board size to shrink to 11","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard W. Gochnauer (director since 2008) and Kathleen W. Hyle (since 2010) will retire at the Annual Meeting on March 6, 2025.","Board size reduces from 13 to 11 effective the date of the Annual Meeting.","Gochnauer served on Audit and Compliance/Risk Committees; Hyle chaired Compensation/Succession and served on Executive and Finance Committees.","Both will continue serving until the meeting; no disagreements with the Company reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170194,"accession_number":"0001104659-25-000366","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Cencora completes $4.4B acquisition of Retina Consultants of America; raises FY2025 adjusted EPS guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cencora acquires ~85% interest in Retina Consultants of America for $4.4B cash outlay, with post-closing adjustment.","RCA becomes Cencora subsidiary; certain RCA physicians and management retain minority equity interest.","FY2025 adjusted diluted EPS guidance raised to $15.15-$15.45 from prior $14.80-$15.10, reflecting RCA contribution and momentum.","Acquisition expands Cencora's specialty leadership, MSO solutions, and value for physicians and patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187209,"accession_number":"0001104659-24-127207","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["1.01","2.03","7.01","8.01","9.01"],"status":"ready","headline":"Cencora closes $1.8B senior notes offering to fund Retina Consultants of America acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M 4.625% notes due 2027, $600M 4.850% notes due 2029, $700M 5.150% notes due 2035.","Net proceeds to finance majority acquisition of Retina Consultants of America and related fees/expenses.","Terminated remaining $1.8B bridge financing commitments upon receiving note proceeds.","Notes are unsecured, rank equally with existing unsecured debt; structurally subordinated to subsidiary liabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187208,"accession_number":"0001104659-24-125357","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cencora prices $1.8B debt offering in three tranches to fund Retina Consultants acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M 4.625% senior notes due 2027, $600M 4.850% notes due 2029, $700M 5.150% notes due 2035 priced.","Net proceeds estimated at $1.79B from the registered public offering.","Proceeds will finance the acquisition of majority of Retina Consultants of America and related costs.","Offering expected to close December 9, 2024, subject to customary conditions.","Joint book-running managers: BofA Securities, Citigroup, J.P. Morgan, Wells Fargo Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187207,"accession_number":"0001104659-24-123450","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cencora enters $1.5B term loan and $1.0B revolver to fund Retina Consultants of America acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.5B senior unsecured term loan entered Nov 26, 2024; matures 3 years from draw.","$1.0B 364-day senior unsecured revolving credit facility, available after acquisition closing.","Term loan proceeds to pay portion of cash consideration for Retina Consultants of America acquisition.","Bridge financing commitments automatically reduced by $1.5B from $3.3B to $1.8B.","Covenants include leverage ratio not exceeding 3.75x (4.00x at election during closing quarter)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187206,"accession_number":"0001104659-24-115578","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cencora to acquire Retina Consultants of America for $4.6B, ~85% ownership, accretive $0.35","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value of $4.6B cash; expected cash outlay ~$4.3B after physician/management rollover and fees.","Cencora will hold ~85% ownership; up to $500M contingent consideration in FY2027-2028 tied to predefined objectives.","Transaction expected ~$0.35 accretive to adjusted diluted EPS in first 12 months post-close.","RCA operates nearly 300 retina specialists across 23 states, 2M+ annual visits, 40 clinical trial sites.","Funding via cash on hand and new debt; $3.3B bridge financing obtained; fiscal 2025 guidance excludes deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187205,"accession_number":"0001140859-24-000148","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q4 adjusted EPS $3.34, revenue $79.1B (+14.7% YoY); dividend up 8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $0.02 vs $1.72 prior year; adjusted EPS $3.34 (+16.8% YoY) on revenue $79.1B (+14.7% YoY).","FY2024 adjusted EPS $13.76 (+14.8% YoY); revenue $294.0B (+12.1% YoY).","Quarterly dividend increased by 8%; specific amount, payable and record dates not disclosed.","Acquisition of Retina Consultants of America announced; no deal value or terms provided."],"consensus_eps_estimate":null,"consensus_eps_actual":7.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":293958599000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187204,"accession_number":"0001104659-24-108579","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cencora amends revolver and securitization facilities, extends maturities to 2029/2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility maturity extended to October 9, 2029; facility fees reduced.","Canadian reference rate changed from CDOR to CORRA for CAD loans.","Securitization facility term extended to October 8, 2027; base limit $1.45B with $250M seasonal option.","Interest on revolver: 80.5–122.5 bps over Term SOFR (or CORRA/Euribor) based on debt ratings; facility fee 7–15 bps.","Up to $100M in letters of credit available under the revolver; funds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203720,"accession_number":"0001104659-24-097135","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Cencora raises FY2024 adjusted EPS guidance to $13.60-$13.70; extends Evernorth supply deal through 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Adjusted diluted EPS for FY2024 raised to $13.60-$13.70 from prior $13.55-$13.65.","FY2025 adjusted operating income and EPS growth expected at bottom of long-term targets (5-8% and 8-12%).","FY2025 headwinds include COVID products and potential June 2025 loss of an oncology customer after its pending acquisition.","Extended pharmaceutical supply agreement with Evernorth Health Services for three additional years through September 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203719,"accession_number":"0001104659-24-090498","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["1.01","5.02","5.03","9.01"],"status":"ready","headline":"Cencora enters into indemnification agreements, amends shareholder pact with WBA, approves executive employment deals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cencora entered into indemnification agreements with board members and executive officers, effective August 13, 2024.","Amendment No. 2 with Walgreens Boots Alliance increases maximum board size from 11 to 14 plus WBA-designated directors.","New employment agreements approved for CFO James F. Cleary and CLO Elizabeth S. Campbell, effective August 13, 2024.","Board adopted over 20 amendments to bylaws, clarifying stockholder meeting, director nomination, and remote meeting procedures.","Executive severance includes two-year base salary continuation, prorated bonus, and COBRA coverage, subject to release conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203718,"accession_number":"0001104659-24-089929","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora elects Frank Clyburn to its board of directors, effective Oct 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frank Clyburn appointed as independent director, effective October 1, 2024.","Board will increase from 11 to 13 members as a result.","Clyburn previously CEO of IFF and EVP at Merck; brings pharmaceutical industry expertise.","Compensation follows non-employee director policy, pro-rated until 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203717,"accession_number":"0001104659-24-085811","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Cencora repurchases $250M shares from Walgreens; stake reduced to 10.2%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 1,039,242 shares from Walgreens Boots Alliance Holdings for ~$250M at market price.","Repurchase price per share equal to Walgreens' concurrent Rule 144 sale of 3,398,929 shares.","After both transactions, Walgreens holds 19,980,000 shares, ~10.2% of Cencora's outstanding.","Repurchase funded from cash on hand; shares held in treasury under existing buyback program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203716,"accession_number":"0001140859-24-000117","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q3 adjusted EPS $3.34 (+14.4%), revenue $74.2B (+10.9%); raises FY2024 guidance to $13.55-$13.65","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $74.2B (+10.9% YoY); GAAP diluted EPS $2.42 vs $2.35; adjusted diluted EPS $3.34 vs $2.92.","FY2024 adjusted diluted EPS guidance raised to $13.55-$13.65 from $13.35-$13.55.","CEO succession: Steven H. Collis to become Executive Chairman Oct 1; COO Bob Mauch becomes CEO.","GAAP operating income $672M; adjusted operating income $878M.","Net income attributable to Cencora: $483M GAAP, $668M adjusted; diluted shares 200M."],"consensus_eps_estimate":null,"consensus_eps_actual":7.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":214908493000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203715,"accession_number":"0001104659-24-084351","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K/A","filed_at":"2024-07-31T23:59:59+00:00","items":["1.05"],"status":"ready","headline":"Cencora confirms PII/PHI exfiltration in Feb 2024 cyber incident; notifications ongoing","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Exfiltrated data includes personally identifiable and protected health information, most from patient support subsidiary.","Notifications have been sent to affected individuals and regulatory agencies; data review continues.","No evidence data has been or will be publicly disclosed; containment and remediation are ongoing.","Incident has not materially impacted operations or financial condition, per company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220272,"accession_number":"0001104659-24-065122","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cencora repurchases $400M in shares from Walgreens, raises FY2024 adjusted EPS guidance to $13.35-$13.55","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 1,859,390 shares at $215.1244/share from Walgreens Boots Alliance Holdings for ~$400M.","Walgreens retains 24,418,171 shares (~12% of outstanding) after the transaction.","FY2024 adjusted diluted EPS guidance raised to $13.35-$13.55 from $13.30-$13.50 (prior range).","Company has completed ~$550M in share repurchases in May 2024.","Repurchased shares will be held in treasury; transaction closed on May 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220271,"accession_number":"0001140859-24-000081","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cencora EVP & Chief Communications/Admin Officer Gina Clark to retire Sept 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gina K. Clark, EVP & Chief Communications/Administrative Officer, intends to retire effective September 30, 2024.","Retirement not due to any disagreement with management or Board regarding operations, finances, policies, or practices.","No successor has been announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220270,"accession_number":"0001140859-24-000070","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Cencora Q2 revenue $68.4B, up 7.8% YoY; adj diluted EPS $3.80, up 8.6%; FY2024 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $68.4B for quarter ended March 31, 2024, +7.8% YoY.","GAAP diluted EPS of $2.09 (down from $2.13 prior year); adjusted diluted EPS $3.80 (up from $3.50).","Fiscal 2024 adjusted diluted EPS guidance raised to $13.30-$13.50 from previous $13.25-$13.50.","Operating income $553M GAAP, $1.0B adjusted; net income attributable to Cencora $421M GAAP, $765M adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":5.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":140667140000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220269,"accession_number":"0001104659-24-050615","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Cencora extends securitization facility to Oct 2026, adds U.S. Bank and Truist as purchasers","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended receivables purchase agreement to extend facility termination date from Oct 2025 to Oct 21, 2026.","Added U.S. Bank National Association and Truist Bank as committed/uncommitted purchasers and purchaser agents.","Removed Mizuho Bank as a committed/uncommitted purchaser and purchaser agent.","Facility base limit remains $1.45 billion with an option for $250 million seasonal increase during Dec and Mar quarters.","Technical updates to reflect company name change to Cencora, Inc. in related agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239950,"accession_number":"0001104659-24-035043","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Cencora shareholders approve officer exculpation, all 11 directors elected at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Item 4 (officer exculpation amendment) approved: 156M for, 19.4M against, 9M broker non-votes.","All 11 director nominees elected with large majorities; Steven Collis received most against votes (7.1M).","Advisory vote on executive compensation (say-on-pay) approved: 164.3M for, 10.9M against.","Ernst & Young ratified as auditor for FY2024: 170.7M for, 13.9M against.","Shareholder proposal on director voting standard not presented; would have lost 1.3M for vs 173.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239942,"accession_number":"0001104659-24-035045","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K/A","filed_at":"2024-03-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cencora discloses CEO succession compensation: Mauch $1.35M salary, Collis $1M as Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert P. Mauch appointed CEO effective Oct 1, 2024; base salary $1,350,000; joins Board.","Steven H. Collis to serve as Executive Chairman for one year after Oct 1; base salary $1,000,000.","Both eligible for same short/long-term incentive plans as other senior executives.","Mauch severance: two years salary plus two times target bonus; COBRA coverage.","Collis transition: current comp through Sept 30, then $1M base as Executive Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239949,"accession_number":"0001104659-24-033278","cik":1140859,"company_name":"Cencora, Inc.","ticker":"COR","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Cencora CEO Collis to retire Oct 1, COO Mauch to become President and CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven H. Collis will retire as CEO on Oct 1, 2024, becoming Executive Chairman for one year.","Robert P. Mauch (current COO) succeeds Collis as President and CEO, joining the Board on the same date.","Mauch, 57, holds a Pharm.D. and Ph.D., joined Cencora via 2007 Xcenda acquisition.","Company reaffirms fiscal 2024 guidance as outlined on Jan 31, 2024.","Collis led Cencora since 2011, tripling annual revenue to over $250 billion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":51535336960.954575,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-03-12T23:59:59+00:00|239949"}